1% of the physicians. 77.4% of the physicians claimed that they often prescribe generic medicines. Most patients (78%) accepted generic substitution and believed that it can provide significant saving. Surveyed patients (78%) agreed that they should have the option of choosing between generic and originator and 74% believed that physicians should give them that choice. These results showed a significant statistical correlation with the monthly income of the patient, percentage

medicine cost they pay and number of medicines prescribed (P < 0.05). However, Physicians mostly (72.1%) opposed to generic substitution being allowed upon patient BIBF-1120 request. Most pharmacists had a positive view on generic medicines in general with 87.7% of the respondents believing that a generic medicine is bio-equivalents to the originator. The majority pharmacists (90.1%) were in favour

of implementing a compulsory generic prescribing policy. More than 80% of the pharmacists supported generic substitution in most cases. Similarly, physician predominantly (80.1%) welcomed the implementation Forskolin price of prescribing using International Nonproprietary Name (INN) to support generic supply. More than two thirds of the physicians (69.5%) accepted generic substitution by pharmacists. More physicians in the public sector (40.2%) accepted generic substitution compared to the private sector (29.3%) (P < 0.05). The findings Amylase from this study showed the positive attitude of all stakeholders involved towards generic medications and their high willingness and acceptance of strategies that encourage generic utilisation in Jordan such as generic substitution and INN prescribing. All these strategies would help reduce the high expenditure on drugs in Jordan. These insights will help policy makers in Jordan to develop a robust generic policy which could be used

to achieve greater clinical effectiveness and economic efficiency from drug prescribing. 1. Holmes D. R., Becker J. A., Granger C. B., Limacher, M. C., Page R. L. Sila, C. ACCF/AHA 2011 Health Policy Statement on Therapeutic Interchange and Substitution.Circulation. 2011; 124: 1290–1310. 2. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies.Croatian Medical Journal 2002; 43: 462–469. Rosario Sorrentino, Ilaria Uomo, Maurizio Pastorello Department of Pharmacy ASP Palermo, Sicily, Italy Biosimilar erythropoietins have lower pricing than originator medicines but they are still under-prescribed by the physicians, expecially in Italy. Interchangeability from one branded medicine to a biosimilar must be made only by the physician, such as determined by the Italian Medicines Agency in agreement with other international Position Papers.